RemeGen Co. Ltd. Class A
688331
주식 순위
#2477
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
주가
$14.07
마지막 동기화: 2026-10-19
시가총액
$7.88B
변동 (1일)
-2.90%
변동 (1년)
6.01%
국가
CN
거래 RemeGen Co. Ltd. Class A (688331)
카테고리
Healthcare
RemeGen Co. Ltd. Class A (688331)의 배당 수익률 기록
RemeGen Co. Ltd. Class A (주식 심볼: 688331)의 배당 수익률 (TTM)은 2023-12-31 기준으로 0.05%입니다.
지난 5년 평균 배당 수익률: 0.10%
지난 5년 평균 배당 수익률: 0.10%
RemeGen Co. Ltd. Class A (688331)의 배당 수익률 기록: 2018 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
| 연도 | 배당 수익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2024 | 0.43% | 760.00% |
| 2023 | 0.05% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
유사 기업 또는 경쟁사의 배당 수익률 (TTM)
| 회사 | 배당 수익률 | 국가 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
